Here is the headline for Georgia Medicare clinical laboratory services: for lab tests billed under the Medicare Clinical Laboratory Fee Schedule (CLFS), you usually pay $0. That means no Part B deductible and no 20 percent coinsurance on the vast majority of routine lab work Georgia seniors get every year, from a cholesterol panel to a diabetes A1c to an INR draw. So if you have Medicare in Georgia and your doctor orders blood work, a biopsy, a Pap smear, or a screening mammogram, this guide explains what Original Medicare pays for and what, in the few cases that carry a cost, you actually owe.
Medicare Part B has covered diagnostic laboratory tests since 1965 under Section 1861(s)(3) of the Social Security Act. This guide walks a Georgia beneficiary through what that means in plain terms: which lab tests are covered and which are not, why a few still carry a coinsurance (anatomic pathology read by a pathologist is paid differently), how the preventive screening tests work and how often you can get them, how Palmetto GBA processes and sometimes denies Georgia lab claims, and exactly what to do when a claim is denied. Four worked examples follow real Georgia scenarios, from annual blood work in Atlanta to homebound monitoring in Athens, and an FAQ closes the rest.
What Georgia Medicare Clinical Laboratory Services Cover, and the Law Behind It
The Medicare clinical laboratory services benefit rests on several layers of law that have accumulated since Medicare began in 1965. The layers matter because coverage disputes are common, particularly for tests not spelled out in a National Coverage Determination and for tests whose coverage depends on a specific diagnosis.
Section 1861(s)(3) of the Social Security Act, codified at 42 U.S.C. 1395x(s)(3), is the foundation that makes diagnostic laboratory tests a Medicare Part B benefit. It covers tests furnished by independent laboratories, hospital outpatient laboratories, and physician office laboratories. Coverage is limited to tests that meet the Section 1862(a)(1)(A) reasonable-and-necessary standard plus any applicable National or Local Coverage Determination.
Section 1833(h) of the Social Security Act, codified at 42 U.S.C. 1395l(h), establishes the Clinical Laboratory Fee Schedule. The CLFS was enacted by the Deficit Reduction Act of 1984, replacing an older reasonable-charge method with a fee schedule, later consolidated to a single national schedule. The CLFS pays for "clinical diagnostic laboratory tests" (CDLTs): chemistry panels, hematology, microbiology, immunology, urinalysis, molecular pathology, and other tests that generally do not require a pathologist's interpretation.
Critically, the zero cost-sharing has two statutory legs. Section 1833(a)(1)(D) sets Medicare's payment for a clinical diagnostic laboratory test at 100 percent when payment is made on an assignment-related basis, so the coinsurance that applies to most Part B services doesn't apply. Section 1833(b)(3) says the Part B deductible does not apply to those same tests, so the deductible isn't a hurdle you clear first.Centers for Medicare & Medicaid Services. (n.d.). Medicare.gov — Diagnostic laboratory tests. medicare.gov. Retrieved Jul 10, 2026, from https://www.medicare.gov/coverage/diagnostic-laboratory-tests By contrast, services paid under the Medicare Physician Fee Schedule follow standard Part B rules: after you meet the annual deductible ($283 in 2026), you owe 20 percent of the Medicare-approved amount.Centers for Medicare & Medicaid Services. (2026). 2026 Medicare Parts A & B Premiums and Deductibles. cms.gov. Retrieved Sep 4, 2026, from https://www.cms.gov/newsroom/fact-sheets/2026-medicare-parts-b-premiums-deductibles
Section 1834A of the Social Security Act, codified at 42 U.S.C. 1395m-1, is the reform added by the Protecting Access to Medicare Act of 2014 (PAMA 2014). It requires "applicable laboratories" to report private payer rate and volume data for each CLFS billing code, and authorizes CMS to set each rate at a weighted median of those private rates.
Section 1861(nn) establishes screening Pap smear and screening pelvic examination as covered preventive services. Screening mammography is covered under 42 CFR 410.34, and colorectal cancer screening under Section 1834(g). These preventive services are discussed in detail below.
Section 1862(a)(1)(A) of the Social Security Act is the reasonable-and-necessary standard. Even a test technically within the CLFS is not paid unless it was reasonable and necessary for the patient's diagnosis or treatment.
Section 1869(f) of the Social Security Act frames National Coverage Determinations (NCDs), issued by CMS and applied nationally, and Local Coverage Determinations (LCDs), issued by Medicare Administrative Contractors and applied only within a jurisdiction.
42 CFR 410.32 requires that diagnostic tests be ordered by the treating physician for diagnosing or treating an illness or injury, the mechanism that prevents standing orders and mass screening unrelated to clinical care.
42 CFR 410.33 establishes the Independent Diagnostic Testing Facility (IDTF) framework, with 14 performance standards. 42 CFR Part 414, Subpart G implements the CLFS payment methodology. 42 CFR Part 493 implements the Clinical Laboratory Improvement Amendments of 1988 (CLIA), the quality and personnel standards for every lab testing human specimens.
The Clinical Laboratory Fee Schedule and PAMA 2014 Market-Based Reform
The Clinical Laboratory Fee Schedule pays for clinical diagnostic laboratory tests (CDLTs): automated chemistry panels, hematology, microbiology, immunology, urinalysis, molecular pathology, and similar tests that generally do not require a pathologist's interpretation. Anatomic pathology (biopsy interpretation, cytology review, immunohistochemistry) is paid under the Medicare Physician Fee Schedule instead, which is why those services carry a coinsurance while CLFS tests do not.
Pre-2018 CLFS methodology
From 1984 through 2017, the CLFS operated as a national fee schedule with annual updates tied to the Consumer Price Index or, in some years, frozen or cut by Congress. The base rates were largely set in 1984 with adjustments over the decades. By the early 2010s, multiple studies found Medicare CLFS rates substantially exceeded what private insurers paid for the same tests.
PAMA 2014 Section 216 reform
The Protecting Access to Medicare Act of 2014 ordered fundamental reform by adding Section 1834A to the Social Security Act, establishing a market-based payment method. The mechanism works like this: applicable laboratories (those meeting defined revenue thresholds) collect private payer rate and volume data for each billing code during a data collection period; they report it to CMS; CMS calculates a weighted median of the private rates; and the weighted median becomes the new CLFS rate. To prevent abrupt disruption, annual payment reductions are capped by statute.
Reporting delays and methodology challenges
The PAMA reform has been delayed repeatedly. The data reporting periods were postponed by successive appropriations acts and continuing resolutions to give CMS and Congress time to revisit the methodology, particularly the definition of "applicable laboratory" (hospital outreach laboratories were largely excluded from the original reporting, raising questions about how representative the data was). None of this changes what a beneficiary pays.
Advanced Diagnostic Laboratory Tests (ADLTs)
Section 1834A created a separate pricing path for Advanced Diagnostic Laboratory Tests, defined as clinical diagnostic tests that are offered and furnished only by a single laboratory, covered under Medicare, and either molecular analyses of multiple biomarkers or otherwise novel tests cleared or approved by the FDA. For an ADLT, the first three quarters are priced at the laboratory's list price, after which the test transitions to market-based rates.
Cost-sharing exemption
PAMA did not remove the cost-sharing exemption. For tests furnished on or after January 1, 2017, the payment rule sits in clause (D)(i)(II) of Section 1833(a)(1), which covers tests paid under Section 1834A: Medicare pays a clinical diagnostic laboratory test at 80 percent, or at 100 percent when payment is made on an assignment-related basis, and in that case the coinsurance that applies to most Part B services doesn't apply. Section 1833(b)(3) separately keeps the Part B deductible off those tests. Both legs carry the assignment condition, which is why Medicare says you usually, rather than always, pay nothing for a Medicare-covered diagnostic lab test a doctor or other health care provider ordered.Centers for Medicare & Medicaid Services. (n.d.). Medicare.gov — Diagnostic laboratory tests. medicare.gov. Retrieved Jul 10, 2026, from https://www.medicare.gov/coverage/diagnostic-laboratory-tests
That stands in contrast to the standard Part B rule (the annual deductible plus 20 percent coinsurance) that applies to most other outpatient services, which is why the exemption is the single most important cost rule in the Medicare laboratory benefit.Centers for Medicare & Medicaid Services. (2026). 2026 Medicare Parts A & B Premiums and Deductibles. cms.gov. Retrieved Sep 4, 2026, from https://www.cms.gov/newsroom/fact-sheets/2026-medicare-parts-b-premiums-deductibles
CLIA 1988: Federal Quality Standards for Clinical Laboratories
The Clinical Laboratory Improvement Amendments of 1988 (CLIA) are the federal law behind laboratory quality standards, implemented at 42 CFR Part 493. The details of certificate types, personnel qualifications, proficiency testing, and inspections are technical and mostly matter to the laboratory, not to you as a patient. For a beneficiary the practical step is simple: ask the laboratory whether it holds the CLIA certificate that matches the tests it runs. For program details or to look up a laboratory, see the CMS CLIA program under Where to Get Help below.
National Coverage Determinations for Laboratory Tests
Several National Coverage Determinations specifically address laboratory tests, setting covered indications, frequency limits, and diagnosis-code requirements. Among the most important:
- Prostate-Specific Antigen (PSA): covers PSA testing to diagnose prostate cancer and to monitor patients already diagnosed, with specified indications. Separately, screening PSA is covered once every 12 months for men over age 50 at no cost.Centers for Medicare & Medicaid Services. (n.d.). Prostate cancer screenings - Medicare.gov. medicare.gov. Retrieved Aug 8, 2026, from https://www.medicare.gov/coverage/prostate-cancer-screenings
- Thyroid Testing: covers TSH, free T4, free T3, T3 uptake, total T4, and total T3 for specific indications such as suspected hyper- or hypothyroidism and monitoring of thyroid replacement therapy.
- Lipid Testing: covers total cholesterol, HDL, LDL, and triglycerides for evaluating suspected lipid disorders, monitoring established ones, and cardiovascular risk assessment.
- Glycated Hemoglobin (A1c): covers hemoglobin A1c for diabetes diagnosis and monitoring.
- Blood Counts: covers the complete blood count for specific indications.
- Human Immunodeficiency Virus (HIV): covers HIV testing for diagnosis and monitoring.
- Hepatitis Panel: covers hepatitis testing panels for specific indications.
- Tumor Antigens (CA 125, CA 15-3/27-29, CA 19-9): cover tumor markers for specific oncologic indications.
Each NCD lists the covered ICD-10 diagnosis codes that establish medical necessity. Laboratories and ordering providers must include a covered diagnosis code to avoid a denial.
Local Coverage Determinations Issued by Palmetto GBA for Georgia
Palmetto GBA Jurisdiction J issues Local Coverage Determinations that apply in Georgia, Alabama, and Tennessee, covering laboratory tests not addressed by national NCDs. Examples include:
- Molecular pathology procedures
- Drug testing panels
- Allergy testing
- Vitamin D testing
- Tumor genetic tests
- Genetic testing for hereditary cancer syndromes
LCDs spell out covered and non-covered indications, ICD-10 diagnosis-code requirements, and documentation requirements. Providers should consult the current Palmetto GBA LCD database before billing.
Screening Laboratory Tests and Statutory Frequency Limits
Several preventive laboratory and screening tests are covered at no cost when you meet Medicare's age and frequency rules, provided the doctor accepts assignment.Centers for Medicare & Medicaid Services. (n.d.). Preventive and screening services. medicare.gov. Retrieved Aug 8, 2026, from https://www.medicare.gov/coverage/preventive-screening-services
Screening Pap smear and pelvic exam (Section 1861(nn))
- Covered once every 24 months in most cases.Centers for Medicare & Medicaid Services. (n.d.). Preventive and screening services. medicare.gov. Retrieved Aug 8, 2026, from https://www.medicare.gov/coverage/preventive-screening-services
- Covered once every 12 months if you're at high risk for cervical or vaginal cancer, or of child-bearing age and had an abnormal Pap test in the past 36 months. "High risk" is a defined term under 42 CFR 410.56(b)(2), and it's broader than it sounds: it includes a history of a sexually transmitted disease, being the daughter of a woman who took DES during pregnancy, and not having had three negative Pap smears in the previous 7 years. That last one is the ordinary position of an older woman who stopped being screened, and it puts her on the 12-month schedule.Centers for Medicare & Medicaid Services. (n.d.). Preventive and screening services. medicare.gov. Retrieved Aug 8, 2026, from https://www.medicare.gov/coverage/preventive-screening-services
- HCPCS Q0091 covers obtaining the screening Pap specimen; the Pap test itself is billed separately.
- You pay nothing for the screening.
Screening mammography (42 CFR 410.34)
- A screening mammogram is covered once every 12 months for women age 40 and older, plus one baseline mammogram for a woman ages 35 to 39.Centers for Medicare & Medicaid Services. (n.d.). Mammograms - Medicare.gov. medicare.gov. Retrieved Aug 7, 2026, from https://www.medicare.gov/coverage/mammograms
- HCPCS 77067 covers a bilateral screening mammogram.
- You pay nothing for a screening mammogram when the provider accepts assignment.
- A diagnostic mammogram (for someone with signs or symptoms of breast disease, a personal history of breast cancer or of biopsy-proven benign breast disease, or when the physician judges one appropriate) is not a no-cost preventive service, and that holds even when a screening visit turns into a diagnostic study the same day: after you meet the annual Part B deductible ($283 in 2026), you pay 20 percent of the Medicare-approved amount.Centers for Medicare & Medicaid Services. (n.d.). Mammograms - Medicare.gov. medicare.gov. Retrieved Aug 7, 2026, from https://www.medicare.gov/coverage/mammograms
Colorectal cancer screening (Section 1834(g))
Medicare covers several colorectal screening modalities:
- Fecal occult blood test (FOBT) or fecal immunochemical test (FIT): covered on a set interval for eligible beneficiaries.
- Multi-target stool DNA test (Cologuard): covered on a set interval for eligible beneficiaries.
- Flexible sigmoidoscopy: for people 45 or older, once every 48 or 120 months depending on risk (48 months after a previous flexible sigmoidoscopy or CT colonography, 120 months after a previous screening colonoscopy).Centers for Medicare & Medicaid Services. (n.d.). Preventive and screening services. medicare.gov. Retrieved Aug 8, 2026, from https://www.medicare.gov/coverage/preventive-screening-services
- Screening colonoscopy: no minimum age; once every 24 months if you're at high risk for colorectal cancer, otherwise once every 120 months, or 48 months after a previous flexible sigmoidoscopy. High risk includes having a parent, sibling or child who has had colorectal cancer or an adenomatous polyp, your own history of adenomatous polyps, or inflammatory bowel disease.Centers for Medicare & Medicaid Services. (n.d.). Preventive and screening services. medicare.gov. Retrieved Aug 8, 2026, from https://www.medicare.gov/coverage/preventive-screening-services
If a polyp or other tissue is found and removed during a screening colonoscopy (or a lesion or growth during a flexible sigmoidoscopy), the visit becomes diagnostic. Under a statutory phase-down, the beneficiary pays 15 percent of the Medicare-approved amount for the provider's services in 2026, plus a separate 15 percent facility coinsurance if it's done in a hospital outpatient setting or ambulatory surgical center, with the Part B deductible waived. That share drops to 10 percent for 2027 through 2029 and to nothing from 2030 onward.Centers for Medicare & Medicaid Services. (n.d.). Preventive and screening services. medicare.gov. Retrieved Aug 8, 2026, from https://www.medicare.gov/coverage/preventive-screening-services
Other preventive screening tests
- Cardiovascular (lipid) screening: covered on a set interval for at-risk beneficiaries.
- Diabetes screening: covered for at-risk beneficiaries, with more than one test per year possible based on clinical criteria.
- HIV screening: covered annually for at-risk beneficiaries.
- Hepatitis C screening: one-time for at-risk beneficiaries and annually for those at high risk.
- Lung cancer screening: a low-dose CT once a year, but only if you meet all of Medicare's conditions: you're between 50 and 77, you have no signs or symptoms of lung cancer, you currently smoke or quit within the last 15 years, you have a smoking history of at least 20 pack years, and your provider orders it. Before the first screening you also need an appointment with your provider to discuss its benefits and risks.Centers for Medicare & Medicaid Services. (n.d.). Preventive and screening services. medicare.gov. Retrieved Aug 8, 2026, from https://www.medicare.gov/coverage/preventive-screening-services
The Independent Diagnostic Testing Facility Framework
The Independent Diagnostic Testing Facility (IDTF) is a separate Medicare provider type established at 42 CFR 410.33. IDTFs are fixed-location, mobile, or individual entities that furnish diagnostic procedures under physician supervision. Common examples include freestanding imaging centers, sleep study laboratories, and electrocardiography laboratories.
The 14 IDTF performance standards (42 CFR 410.33(g))
An IDTF must:
- Demonstrate operational capability to furnish every service listed on its enrollment application.
- Comply with applicable federal and state licensure and regulatory requirements.
- Provide complete and accurate information on its enrollment application.
- Maintain a physical site at the location on its enrollment application.
- Maintain a comprehensive liability insurance policy meeting the minimum coverage required by 42 CFR 410.33(g)(5).
- Maintain medical and patient records.
- Comply with the HIPAA privacy and security regulations.
- Operate consistently with applicable state licensure requirements.
- Be open and operating during posted hours.
- Have one or more supervising physicians.
- Permit unannounced site visits by CMS or its agents.
- Provide written notice of changes in operations or ownership.
- Maintain complete documentation.
- Meet other standards as specified in the regulation.
IDTF supervision levels
Diagnostic tests furnished by IDTFs require physician supervision at one of three levels:
- General supervision: the physician must be available by telephone but need not be present.
- Direct supervision: the physician must be in the office suite and immediately available.
- Personal supervision: the physician must be in attendance during the procedure.
Most diagnostic tests require general supervision; certain higher-complexity procedures require direct or personal supervision.
Specimen Collection Fees
Medicare pays separately for specimen collection in defined circumstances:
- HCPCS 36415: routine venipuncture, paid under Part B.
- HCPCS P9612: collection of a capillary blood specimen.
- HCPCS G0471: collection of venous blood by venipuncture in a SNF or home health setting.
- HCPCS P9603 and P9604: travel allowance for collection from a homebound patient or a patient in a SNF.
The travel allowance matters most for mobile phlebotomy serving homebound Georgia beneficiaries. LabCorp and Quest both offer mobile phlebotomy in metro Atlanta, Macon, Savannah, Augusta, and other Georgia cities, and hospital-affiliated home health programs and independent mobile phlebotomy services also reach rural Georgia.
Palmetto GBA and Georgia Medicare Clinical Laboratory Services Claims
Palmetto GBA is the Medicare Administrative Contractor (MAC) for Jurisdiction J, which processes fee-for-service Medicare Part A and Part B claims for Alabama, Georgia, and Tennessee.Centers for Medicare & Medicaid Services. (n.d.). CMS — Who are the MACs: A/B MAC Jurisdiction J (JJ). cms.gov. Retrieved Oct 15, 2026, from https://www.cms.gov/medicare/medicare-contracting/medicare-administrative-contractors/who-are-the-macs-a-b-mac-jurisdiction-j-jj Palmetto also handles appeals, re-openings, provider enrollment, customer service, provider outreach and education, and medical review for the jurisdiction.Centers for Medicare & Medicaid Services. (n.d.). CMS — Who are the MACs: A/B MAC Jurisdiction J (JJ). cms.gov. Retrieved Oct 15, 2026, from https://www.cms.gov/medicare/medicare-contracting/medicare-administrative-contractors/who-are-the-macs-a-b-mac-jurisdiction-j-jj
The redetermination, the first level of appeal, is decided by the same contractor that denied the claim, but it is only the first of five levels: the second, a reconsideration, goes to an independent Qualified Independent Contractor.Centers for Medicare & Medicaid Services. (n.d.). CMS — Who are the MACs: A/B MAC Jurisdiction J (JJ). cms.gov. Retrieved Oct 15, 2026, from https://www.cms.gov/medicare/medicare-contracting/medicare-administrative-contractors/who-are-the-macs-a-b-mac-jurisdiction-j-jj
Palmetto GBA Jurisdiction J contact information is available at palmettogba.com.
Worked Examples: Georgia Medicare Clinical Laboratory Scenarios
The following examples are illustrative and use hypothetical Georgia beneficiaries.
Example 1: Margaret, 78, Atlanta, annual blood work at Piedmont Atlanta
Margaret attends her annual wellness visit at Piedmont Atlanta. Her physician orders a complete blood count (CBC, HCPCS 85025) and a comprehensive metabolic panel (CMP, HCPCS 80053). The phlebotomist draws the specimen and the tests run on Piedmont's automated analyzers.
Billing:
- HCPCS 85025 CBC: paid under CLFS
- HCPCS 80053 CMP: paid under CLFS
- HCPCS 36415 venipuncture: paid under Part B
Margaret's cost: nothing on the lab tests, thanks to the CLFS cost-sharing exemption, and nothing for the yearly Wellness visit itself when her doctor accepts assignment, with the Part B deductible waived. If her doctor adds a test or service during that visit that the preventive benefit doesn't cover, she may owe coinsurance and the Part B deductible may apply, and if Medicare doesn't cover the extra service at all, she may owe the full amount.Centers for Medicare & Medicaid Services. (n.d.). Preventive and screening services. medicare.gov. Retrieved Aug 8, 2026, from https://www.medicare.gov/coverage/preventive-screening-services
Example 2: Robert, 82, Savannah, annual PSA screening at Memorial Health
Robert receives an annual PSA screening as part of preventive care. His physician orders a total PSA (HCPCS 84153) as a screening test, drawn at Memorial Health's outpatient laboratory.
Billing:
- HCPCS 84153 PSA screening: paid under CLFS as a preventive screening
- No cost-sharing under the preventive services rules
If the PSA is elevated and Robert's urologist orders a reflex free PSA (HCPCS 84154), that test is diagnostic rather than screening but is still on the CLFS, so Robert still owes nothing.
Example 3: Charles, 80, Augusta, colorectal cancer with tumor markers and genomics at AU Medical Center
Charles is diagnosed with stage III colon adenocarcinoma after a colonoscopy and biopsy. The oncology team orders several tests:
- Tumor markers: CEA (HCPCS 82378) and CA 19-9 (HCPCS 86301). Paid under CLFS, no cost-sharing.
- Molecular pathology: KRAS, NRAS, and BRAF mutation testing. Paid under CLFS or the Physician Fee Schedule depending on whether interpretation is required.
- Mismatch repair (MMR) immunohistochemistry: HCPCS 88341 per marker. Paid under the Physician Fee Schedule as a pathology professional service.
- Comprehensive genomic profiling: if the oncologist orders an FDA-approved companion diagnostic, the test may qualify as an Advanced Diagnostic Laboratory Test.
Charles's cost: nothing on the CLFS tests, and the standard 20 percent coinsurance after the annual Part B deductible ($283 in 2026) on the Physician Fee Schedule pathology services, covered by his Medigap.Centers for Medicare & Medicaid Services. (2026). 2026 Medicare Parts A & B Premiums and Deductibles. cms.gov. Retrieved Sep 4, 2026, from https://www.cms.gov/newsroom/fact-sheets/2026-medicare-parts-b-premiums-deductibles
Example 4: Henry, 85, Athens, dual-eligible QMB, homebound monthly INR monitoring
Henry is bedbound at home in Athens with atrial fibrillation requiring warfarin and monthly INR monitoring. His physician orders a monthly INR (HCPCS 85610), and LabCorp mobile phlebotomy serves his home.
Billing:
- HCPCS 85610 prothrombin time/INR: paid under CLFS, no cost-sharing
- HCPCS G0471 collection of venous blood in the home: paid under Part B
- HCPCS P9604 travel allowance per visit
Henry is a Qualified Medicare Beneficiary (QMB), one of the Medicare Savings Programs, enrolled in Georgia Medicaid, which covers any Medicare cost-sharing under Section 1902(n)(3)(B). LabCorp must accept the Medicare-allowed amount as payment in full and cannot balance-bill Henry.
Common Mistakes Georgia Medicare Laboratory Beneficiaries Should Avoid
Assuming a non-CLIA-certified laboratory can bill Medicare. Every laboratory testing Medicare specimens must have an appropriate CLIA certificate. Confirm it before service.
Missing the diagnosis-code requirement. Laboratory claims must carry ICD-10 diagnosis codes that establish medical necessity under the applicable NCD or LCD.
Confusing screening with diagnostic testing. Screening tests have specific frequency limits and can carry different cost-sharing.
Not understanding the CLFS cost-sharing exemption. There is normally no Part B deductible and no coinsurance for clinical laboratory tests paid under the CLFS, so a bill for one is worth questioning.
Confusing CLFS with the Physician Fee Schedule. Anatomic pathology (biopsy interpretation, special stains, immunohistochemistry) is paid under the Physician Fee Schedule and carries a coinsurance.
Not appealing a denied lab claim through Palmetto GBA. The first level of appeal (redetermination) is available for any denial.
Failing to get an Advance Beneficiary Notice (ABN) when the lab expects a denial. Without an ABN, the laboratory cannot bill you for a denied service.
Confusing a CLIA Certificate of Waiver with full CLIA certification. Waived-certificate labs may perform only FDA-categorized waived tests.
Missing the COVID-19 testing rules after the public health emergency. The no-cost rule for diagnostic COVID-19 testing applied during the PHE; afterward, standard Part B rules apply to tests not paired with a covered medical visit.
Frequently Asked Questions About Georgia Medicare Clinical Laboratory Services
1. What laboratory tests does Medicare cover?
Medicare Part B covers diagnostic laboratory tests under Section 1861(s)(3) of the Social Security Act, including blood chemistry, hematology, microbiology, immunology, urinalysis, molecular pathology, and pathology. The test must be reasonable and necessary for diagnosis or treatment, ordered by the treating physician, and consistent with any applicable National or Local Coverage Determination.
2. How much do I pay for laboratory tests under Medicare?
For clinical laboratory tests paid under the Clinical Laboratory Fee Schedule, you usually pay nothing: no Part B deductible and no 20 percent coinsurance. For a medically necessary clinical diagnostic laboratory test your doctor or other health care provider ordered, Section 1833(a)(1)(D) has Medicare pay 100 percent when payment is made on an assignment-related basis, so the usual Part B coinsurance doesn't apply, and Section 1833(b)(3) keeps the Part B deductible off the test too. That assignment condition is why the answer is "usually" rather than "always." For pathology services paid under the Medicare Physician Fee Schedule (such as biopsy interpretation), the standard Part B cost-sharing applies (the deductible plus 20 percent coinsurance).Centers for Medicare & Medicaid Services. (n.d.). Medicare.gov — Diagnostic laboratory tests. medicare.gov. Retrieved Jul 10, 2026, from https://www.medicare.gov/coverage/diagnostic-laboratory-tests
3. What is the Clinical Laboratory Fee Schedule?
The Clinical Laboratory Fee Schedule (CLFS), established by Section 1833(h) of the Social Security Act, is the national fee schedule that pays for clinical diagnostic laboratory tests in Medicare. It was enacted by the Deficit Reduction Act of 1984. PAMA 2014 restructured it through Section 1834A, requiring labs to report private payer rates so CMS could set market-based rates.
4. What is CLIA?
The Clinical Laboratory Improvement Amendments of 1988 (Public Law 100-578), codified at 42 U.S.C. 263a, set federal quality and personnel standards for all laboratories testing human specimens. CLIA categorizes tests as waived, moderate-complexity, or high-complexity, with matching personnel and quality requirements. Every lab testing Medicare specimens must hold an appropriate CLIA certificate.
5. What is the screening mammography benefit under Medicare?
Medicare covers a screening mammogram once every 12 months for women age 40 and older, plus one baseline mammogram for a woman ages 35 to 39, at no cost when the provider accepts assignment. A diagnostic mammogram instead costs 20 percent after the Part B deductible. The regulation is 42 CFR 410.34.
6. What is the screening Pap smear benefit under Medicare?
Section 1861(nn) covers a screening Pap smear and pelvic exam once every 24 months in most cases, or once every 12 months if you're at high risk or of child-bearing age with an abnormal Pap test in the past 36 months. Not having had three negative Pap smears in the previous 7 years counts as high risk on its own. You pay nothing for the screening when the provider accepts assignment.Centers for Medicare & Medicaid Services. (n.d.). Preventive and screening services. medicare.gov. Retrieved Aug 8, 2026, from https://www.medicare.gov/coverage/preventive-screening-services
7. What is the colorectal cancer screening benefit under Medicare?
Section 1834(g) covers several colorectal screening options: a fecal occult blood or fecal immunochemical test, a multi-target stool DNA test (Cologuard), flexible sigmoidoscopy, and screening colonoscopy, each with its own frequency and eligibility rules. If a polyp is removed during a screening colonoscopy, you pay 15 percent of the Medicare-approved amount in 2026 (plus a separate 15 percent facility coinsurance in a hospital outpatient setting or surgical center), under a statutory phase-down that drops to nothing from 2030 onward.Centers for Medicare & Medicaid Services. (n.d.). Preventive and screening services. medicare.gov. Retrieved Aug 8, 2026, from https://www.medicare.gov/coverage/preventive-screening-services
8. Who is Palmetto GBA and why does it matter for Georgia laboratory claims?
Palmetto GBA is the Medicare Administrative Contractor for Part B claims in Jurisdiction J: Georgia, Alabama, and Tennessee. Palmetto processes Georgia Part B claims, including laboratory claims, and handles the first level of appeal. Contact information is at palmettogba.com.
9. How do I appeal a denied laboratory claim?
The Medicare appeals process has five levels: (1) redetermination by Palmetto GBA; (2) reconsideration by a Qualified Independent Contractor; (3) a hearing before an Administrative Law Judge if the amount in controversy meets the threshold; (4) the Medicare Appeals Council; and (5) federal district court review. Each level has its own filing deadline, printed on the decision notice. Ask the laboratory whether it obtained an Advance Beneficiary Notice (ABN, CMS-R-131) from you, because that changes who owes the bill.
10. How can a Georgia Medicare beneficiary report laboratory fraud?
Laboratory fraud (unnecessary testing, kickbacks, upcoding, billing for tests not performed, or improper balance billing) can be reported to the HHS Office of Inspector General hotline at 1-800-HHS-TIPS (1-800-447-8477) or to 1-800-MEDICARECenters for Medicare & Medicaid Services. (n.d.). Reporting Medicare fraud & abuse. medicare.gov. Retrieved Sep 2, 2026, from https://www.medicare.gov/basics/reporting-medicare-fraud-and-abuse, or, where Georgia Medicaid is the payer, to the Georgia Attorney General's Medicaid Fraud and Patient Protection Division, the state's Medicaid Fraud Control Unit, at 404-458-2878, ext. 664, Monday through Friday from 8:30 a.m. to 5:00 p.m.U.S. Government Publishing Office. (n.d.). 42 CFR § 1007.3 (eCFR, current) — Statutory basis and organization of rule (State MFCUs). ecfr.gov. Retrieved Sep 4, 2026, from https://www.ecfr.gov/current/title-42/section-1007.3 If you aren't sure a lab bill is wrong, a Georgia SHIP counselor can help you review your Medicare Summary Notice and sort through the bill for free, at 1-866-552-4464, option 4, Monday through Friday from 8 a.m. to 5 p.m.Administration for Community Living. (n.d.). Administration for Community Living — State Health Insurance Assistance Program (SHIP). acl.gov. Retrieved Jul 30, 2026, from https://acl.gov/programs/connecting-people-services/state-health-insurance-assistance-program-ship
Where to Get Help in Georgia
Learn More
Find personalized help navigating Georgia Medicare clinical laboratory benefits at brevy.com.
The information on Brevy.com is for educational purposes only and is not a substitute for professional legal, financial, or medical advice. Rules vary by state and program and change frequently. Always verify with the relevant agency or a qualified professional. Brevy is not a law firm, financial advisor, or healthcare provider.
Still have questions?
Brevy answers from this guide and every other guide here, and can check what you qualify for.